Hemophilia A trials in Spain: Trial Insights

Filters: Condition: Hemophilia A Country / region: Spain Clear all

167 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2002	2
2004	1
2005	2
2006	2
2007	1
2008	2
2009	8
2010	6
2011	6
2012	9
2013	7
2014	10
2015	15
2016	11
2017	6
2018	11
2019	4
2020	11
2021	11
2022	7
2023	11
2024	6
2025	10
2026	7

Trials by status
Category	Trials
Completed	104
Recruiting	15
Active, not recruiting	14
Unknown status	14
Terminated	12
Not yet recruiting	5
Enrolling by invitation	2
Withdrawn	1

Top lead sponsors
Category	Trials
Novo Nordisk A/S	31
Investigación en Hemofilia y Fisioterapia	20
Baxalta now part of Shire	16
Bayer	14
Hoffmann-La Roche	12
Pfizer	10
Swedish Orphan Biovitrum	9
Universidad Católica San Antonio de Murcia	8
Bioverativ, a Sanofi company	4
CSL Behring	4

Top conditions
Category	Trials
Hemophilia A	167
Hemophilia B	26
Blood Coagulation Disorders	11
Coagulation Protein Disorders	10
Arthralgia	9
Joint Diseases	8
Chronic Pain	7
Hematologic Diseases	7
Anxiety Disorders	5
Genetic Diseases, Inborn	5

Trials

Showing 76 to 100 of 167. Each trial links to its page on Pharma Observatory.

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients NCT03695978ObservationalRecruitingOctapharmaStarted 2018
Fascial Therapy in Elbow Hemophilic Arthropathy NCT03009591Not applicableCompletedReal Fundación Victoria EugeniaStarted 2018
Alphanate in Immune Tolerance Induction Therapy NCT03095287Phase 2TerminatedGrifols Therapeutics LLCStarted 2018
The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B NCT03623295ObservationalCompletedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Started 2018
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) NCT03370913Phase 3CompletedBioMarin PharmaceuticalStarted 2017
A Progressive Resistance Training Program in Patients With Haemophilia NCT02781233Not applicableCompletedUniversity of ValenciaStarted 2017
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors NCT03191799Phase 3CompletedHoffmann-La RocheStarted 2017
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors NCT03196297Phase 2CompletedNovo Nordisk A/SStarted 2017
Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia NCT03185897ObservationalCompletedBaxalta now part of ShireStarted 2017
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A NCT03020160Phase 3CompletedHoffmann-La RocheStarted 2017
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products NCT02976753ObservationalCompletedSwedish Orphan BiovitrumStarted 2016
BAX 802 in CHA With Inhibitors NCT02895945Phase 3TerminatedBaxalta now part of ShireStarted 2016
Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT® NCT03006965ObservationalCompletedSpanish Society of Thrombosis and HaemostasisStarted 2016
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis NCT02830477ObservationalCompletedBayerStarted 2016
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A NCT02941354Phase 1CompletedNovo Nordisk A/SStarted 2016
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A NCT02920398Phase 1CompletedNovo Nordisk A/SStarted 2016
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors NCT02847637Phase 3CompletedHoffmann-La RocheStarted 2016
Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients NCT02622646ObservationalUnknown statusHospital Universitario La FeStarted 2016
LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures NCT02548143Phase 3CompletedLaboratoire français de Fractionnement et de BiotechnologiesStarted 2016
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors NCT02795767Phase 3CompletedHoffmann-La RocheStarted 2016
BAX 826 Dose-Escalation Safety Study NCT02716194Phase 1CompletedBaxalta now part of ShireStarted 2016
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment NCT02396862ObservationalCompletedBayerStarted 2015
BAX 855 PK-guided Dosing NCT02585960Phase 3CompletedBaxalta now part of ShireStarted 2015
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors NCT02622321Phase 3CompletedHoffmann-La RocheStarted 2015
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A NCT02615691Phase 3CompletedBaxalta now part of ShireStarted 2015

67 more trials match. See them on Pharma Observatory

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa NCT06716814Status changeRecruiting to Active, not recruitingOctober 22, 2026
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa NCT06716814Enrollment change104 to 89October 22, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory